Clinical Trial: NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | IO Biotech |
| Information Provided By: | IO Biotech |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Official Title
A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
Conditions
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Intervention / Treatment
- Drug: IO102-IO103 in combination with pembrolizumab
Other Study ID Numbers
- IOB-022
- KEYNOTE-D38
Start Date (Actual)
2022-04-11
Primary Completion Date (Actual)
2025-11-30
Study Completion Date (Actual)
2026-02-08
Enrollment (Actual)
63
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | IO Biotech |
| Information Provided By: | IO Biotech |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Official Title
A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
Conditions
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Intervention / Treatment
- Drug: IO102-IO103 in combination with pembrolizumab
Other Study ID Numbers
- IOB-022
- KEYNOTE-D38
Start Date (Actual)
2022-04-11
Primary Completion Date (Actual)
2025-11-30
Study Completion Date (Actual)
2026-02-08
Enrollment (Actual)
63
Study Type
Interventional
Phase
Phase 2